X4 reports Phase I data for RCC candidate

X4 Pharmaceuticals Inc. (Cambridge, Mass.) reported data from 14 evaluable patients with advanced clear cell renal cell carcinoma (RCC) in the Phase I portion of a Phase I/II trial showing that X4P-001-IO plus Inlyta axitinib led to a disease control rate (DCR) of 93% and an objective response rate (ORR) of 29%, including 1 confirmed complete response. The combination was well tolerated with hypertension, diarrhea, fatigue, nausea, decreased appetite, headache and dry eye reported as the most common treatment-related adverse events. The recommended Phase II dose is once-daily 400 mg X4P-001-IO plus twice-daily 5 mg Inlyta.

Data were presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting in Philadelphia...